Previous 10 | Next 10 |
MiMedx Group press release (NASDAQ:MDXG): Q4 GAAP EPS of $0.01 beats by $0.04. Revenue of $67.29M (-1.1% Y/Y) beats by $3.6M. For further details see: MiMedx Group GAAP EPS of $0.01 beats by $0.04, revenue of $67.29M beats by $3.6M
Fourth Quarter Net Sales of $67.4 M illion and Full Year 2021 Net Sales of $258.6 M illion; Reflects a Double-Digit Revenue Increase in the Company's Continuing Portfolio of Products Vibrant Commercial Business is Funding New Product Development Initiativ...
ACAD,ACHC,AGM,AMBA,AMRC,OTCPK:AOIFF,APLS,APPF,APTS,ARCT,ARDX,ASXC,ATRA,AVIR,AY,BANX,BIGC,BLFS,BLNK,BRMK,CAPL,CLDX,CO,CSR,CSTL,DAR,DDD,DNMR,DVAX,ENDP,EVA,FATE,FGEN,FRPT,FSK,GAIA,GDRX,GMRE,GOEV,GPOR,GRPN,HHC,HPQ,HRTX,ICAD,KD,LAZR,LCID,MBI,MDXG,MRTX,NKTR,NMFC,NVAX,NVEE,OCUL,OKE,ONTF,OTIC,PDCE,PG...
Use of MIMEDX PURION ® Processed DHACM Provided Improved Clinical Benefits, Shorter Average Length of Treatment and Increased Quality-Adjusted Life Years MARIETTA, Ga., Feb. 16, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the ȁ...
MARIETTA, Ga., Feb. 14, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report operating and financial results for the fourth quarter ended Decemb...
MIMEDX Primed to Commence Pivotal Phase 3 Clinical Study Program of micronized dehydrated Human Amnion Chorion Membrane (mdHACM) in Knee Osteoarthritis (KOA), Targeting Potential Late-2026 Commercial Launch Double-Digit Growth Objective in 2022 to be Driven by Treatment Transfor...
MARIETTA, Ga., Jan. 04, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that Timothy R. Wright, Chief Executive Officer, Peter M. Carlson, Chief Financial Offi...
MARIETTA, Ga., Dec. 22, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial ...
Ahead of the company’s virtual Investor Day taking place at 9:00 a.m. ET today, MiMedx Group (NASDAQ:MDXG) has revised its guidance for adjusted net sales for fiscal 2021 to $253M – $258M from the previously announced projection of $245M – $255M. For fiscal 2020, the comp...
Company to Share Probability Values from its Knee Osteoarthritis (KOA) Study; Analyses Conducted Support Confidence in Initiation of Confirmatory Phase 3 Trials in 2022 Commercial Business Strategy Demonstrates Sustainable Double-digit Growth Potential in Multiple Underpenetrate...
News, Short Squeeze, Breakout and More Instantly...
Study adds to the Company’s growing body of evidence and expands the understanding of the regulatory capabilities of its DHACM and LHACM allografts on the fibrotic process Marks MIMEDX’s first publication in the 5 th most-cited journal in the world MARIET...
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...
MARIETTA, Ga., July 17, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30, 2024 after the market close on Wednesday, July 3...